Propel Bio Management, LLC Athira Pharma, Inc. Transaction History
Propel Bio Management, LLC
- $86.1 Billion
- Q1 2025
A detailed history of Propel Bio Management, LLC transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 1,492,792 shares of ATHA stock, worth $597,116. This represents 0.49% of its overall portfolio holdings.
Number of Shares
1,492,792
Previous 1,492,792
-0.0%
Holding current value
$597,116
Previous $876 Million
51.44%
% of portfolio
0.49%
Previous 0.87%
Shares
1 transactions
Others Institutions Holding ATHA
# of Institutions
59Shares Held
18.3MCall Options Held
14.3KPut Options Held
4.4K-
Perceptive Advisors LLC New York, NY5.4MShares$2.16 Million0.06% of portfolio
-
Bml Capital Management, LLC Zionsville, IN3.2MShares$1.28 Million0.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.54MShares$615,1650.0% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$597,1160.02% of portfolio
-
Black Rock Inc. New York, NY676KShares$270,4970.0% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $15.1M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...